ABILITYPHARMA

AbilityPharma is a clinical stage biopharmaceutical company focused on autophagy to treat cancer

PIPELINE

ABTL0812, first-in-class, is currently in phase 2 clinical trials in lung cancer and endometrial cancer patients in Spain and France

SCIENCE

AbilityPharma investigates cancer drugs inducing cytotoxic autophagy selectively in cancer cells

AbilityPharma is a biopharmaceutical company developing new first-in-class candidates to treat cancer. We are focused on autophagy as a new therapeutic strategy to induce cancer cell death. Based on this novel mechanism of action, we are generating a portfolio of new drugs targeting oncological unmet needs.

Media Center

12.09.2019

News

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019

News

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
22.11.2019

In the media

Ability Pharma receives the acknowledgement from Cerdanyola Empresarial + info
13.09.2019

In the media

Ability reinforces the direction and rises 2 million euros from Inveready and Everis + info
March

Events

BIO-Europe Spring. Paris (France) + info
February

Events

15th Biomarkers Series UK. Manchester (United Kingdom) - Marc Yeste, PhD: Pharmacodynamic biomarkers associated to ABTL0812, a phase 2 clinical stage pro-autophagy anticancer drug + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG